RM
RME.F ResMed Inc
- Market cap
- EUR 30.0B
- P/E
- 22.6x
- P/B
- 5.52x
- ROE
- 28.1%
- Dividend yield
- 1.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is RME.F undervalued?
Graham numberRME.F trades 135.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ResMed Inc fundamental analysis
No fundamental analysis for ResMed Inc yet.
ResMed Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ResMed Inc
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl…
Full company profileResMed Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ResMed Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.07B | 2.34B | 2.61B | 2.96B | 3.20B | 3.58B | 4.22B | 4.69B | 5.15B | 5.65B | 5.66B |
| Gross Profit | 1.20B | 1.36B | 1.54B | 1.72B | 1.84B | 2.02B | 2.36B | 2.66B | 3.05B | 3.45B | 3.48B |
| Operating Income | 457M | 560M | 636M | 809M | 912M | 1.00B | 1.15B | 1.38B | 1.69B | 1.91B | 1.81B |
| EBITDA | 559M | 670M | 706M | 955M | 1.10B | 1.19B | 1.35B | 1.60B | 1.92B | 2.15B | 2.38B |
| Net Income | 342M | 316M | 405M | 622M | 475M | 779M | 898M | 1.02B | 1.40B | 1.52B | 1.67B |
| EPS | 2.41 | 2.21 | 2.82 | 4.29 | 3.26 | 5.32 | 6.10 | 6.95 | 9.57 | 11 | 12 |
| Balance Sheet | |||||||||||
| Total Assets | 3.47B | 3.06B | 4.11B | 4.59B | 4.73B | 5.10B | 6.75B | 6.87B | 8.17B | 8.97B | 8.21B |
| Total Liabilities | 1.51B | 1.00B | 2.04B | 2.09B | 1.84B | 1.74B | 2.62B | 2.01B | 2.21B | 2.38B | 2.26B |
| Shareholders' Equity | 1.96B | 2.06B | 2.07B | 2.50B | 2.89B | 3.36B | 4.13B | 4.86B | 5.97B | 6.59B | 5.95B |
| Cash & Short-term Investments | 822M | 189M | 147M | 463M | 295M | 274M | 228M | 238M | 1.21B | 1.47B | 1.01B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 414M | 505M | 459M | 802M | 737M | 351M | 693M | 1.40B | 1.75B | 1.81B | 1.69B |
| Capital Expenditure | 62.2M | 62.6M | 68.7M | 95.3M | 103M | 135M | 120M | 115M | 101M | 177M | 205M |
| Free Cash Flow | 343M | 434M | 382M | 696M | 620M | 195M | 559M | 1.29B | 1.65B | 1.63B | 1.49B |
| Ratios | |||||||||||
| ROE | 17.5% | 15.3% | 19.5% | 24.9% | 16.4% | 23.2% | 21.7% | 21.0% | 23.5% | 23.1% | 28.1% |
| ROA | 9.9% | 10.3% | 9.8% | 13.6% | 10.0% | 15.3% | 13.3% | 14.9% | 17.1% | 17.0% | 20.4% |
| Net Profit Margin | 16.6% | 13.5% | 15.5% | 21.0% | 14.8% | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% | 29.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ResMed Inc dividends
- Dividend yield
- 1.13%
- Forward dividend
- 2.36 EUR
- Payout ratio
- 23.0%
- Ex-dividend date
- Nov 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 350M | 2.42 | 23.0% |
| 2025 | USD 311M | 2.12 | 22.2% |
| 2024 | USD 282M | 1.92 | 27.7% |
| 2023 | USD 258M | 1.76 | 28.8% |
| 2022 | USD 245M | 1.68 | 31.5% |
| 2021 | USD 227M | 1.56 | 47.8% |
| 2020 | USD 225M | 1.55 | 36.2% |
| 2019 | USD 212M | 1.47 | 52.3% |
| 2018 | USD 199M | 1.40 | 63.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 31, 2010.
Who owns ResMed Inc
- Insiders 0.51%
- Institutions 71.90%
- Public & others 27.59%
- Shares outstanding 141M
- Free float 140M
ResMed Inc company profile
- Company name
- ResMed Inc
- Ticker
- RME.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 11,370
- Fiscal year end
- June
- Address
- 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123
- Phone
- 858-836-5000
- Website
- resmed.com
About ResMed Inc
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
ResMed Inc management
10- Mr. Michael J. Farrell BE, MBA, SMCEO & Chairman · born 1972
- Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScDFounder, Chair Emeritus & Non-Executive Director · born 1942
- Mr. Aaron BloomerChief Financial Officer · born 1986
- Mr. Michael J. RiderChief Legal Officer & Secretary · born 1958
- Mr. Brett A. SandercockAdvisor · born 1967
- Mr. Justin LeongChief Product Officer · born 1977
- Mr. Alastair RobertsonChief Information Officer
- Ms. Sallilyn SchwartzChief Communications & Investor Relations Officer
- Mr. Jim EllisChief Compliance Officer
- Ms. Yvonne-Katrin PucknatChief Marketing Officer · born 1976